Please assess the completion status of the following clinical trial:

Trial Title: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study related procedures.~* Patients (either sex) must be 18 years or older.~* Patients must be suffering from symptoms of diarrhoea and/or flushing at the time of study enrolment.~* Patients must have a documented diagnosis of a functioning midgut NET.~* In order to avoid patients with rapidly progressing tumours, only patients with well or moderately differentiated tumours and with a Ki67 proliferation index of \<20% will be recruited.~* The clinically appropriate treatment for the patient must be therapy with a somatostatin analogue.~* Patients must have had either a positive somatostatin receptor scintigraphy result or a positive 68Gallium-DOTATATE PET imaging result.~Exclusion Criteria:~* If the patient is at risk of pregnancy or is breast feeding, unless treatment with Somatuline Autogel is clearly needed (as determined by the clinician).~* The patient is, in the opinion of the investigator, unable to comply fully with the protocol and the study instructions, or present any concomitant condition which could compromise the objectives of the study and/or preclude the protocol-defined procedures (e.g. severe medical conditions, brain metastases, psychiatric disorders, active or uncontrolled infection, known pituitary disease).~* The patient has been treated with any other unlicensed drug within the last 30 days before study entry or will require a concurrent treatment with any other experimental drugs or treatments.~* The patient has been treated with a somatostatin analogue prior to study entry, unless a washout period of at least 2 weeks for subcutaneous octreotide, or at least 6 weeks for a single dose of long acting somatostatin analogue has occurred.~* The patient has received interferon, chemotherapy, chemoembolisation or radionuclide therapy within 3 months prior to study entry.~* The patient has a history of hypersensitivity to drugs with a similar chemical structure.~* Females of childbearing potential must be using oral, double barrier or injectable contraception. Non childbearing potential is defined as being post-menopause for at least 1 year, surgical sterilisation or hysterectomy at least three months before the start of the study.~* The patient has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Somatuline Autogel® (Type: EXPERIMENTAL): Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)

Based on this trial design, predict the completion outcome and termination type (if applicable).